VPX Meltdown Clinical Trial, 120 capsules

Retail Price:	$64.99
Sale Price:	$34.99
Item #:	VPX123
Package Insurance?:	Yes (+1.99)No Thanks
Enter Quantity:	1 for $34.992 for $69.983 for $104.974 for $139.965 for $174.956 for $209.947 for $244.938 for $279.929 for $314.9110 for $349.90

VPX Funds Clinical Trial
July 16, 2008

It may surprise you to know that the majority of supplement companies in our industry do not fund research on their products. Yes, many companies use science “sounding” names for their brands, and use “science jargon” in their embarrassing-looking ads! Okay, enough bashing these poor bastards. If you look further into the science journals, you will see that there are just a handful of supplement companies that actually fund clinical research on their products. More than 90% of the companies in our industry have never funded one university study! When a company spends money to fund a clinical trial on one of their products, they should be applauded. At a recent science conference called the “5th Annual International Society of Sports Nutrition Conference” (try saying that name while chomping on a MET-Rx bar), researchers presented a study on VPX’s (www.vpxsports.com) newest fat burner called MELTDOWN®.

THE MELTDOWN STUDY

The clinical trial was performed at the College of New Jersey, where investigators discovered that MELTDOWN® produced significant increases in metabolic rate. In this study, researchers examined the acute (immediate) effect of MELTDOWN on resting oxygen uptake, respiratory quotient (which is a fancy test scientists use to measure fat utilization), and caloric expenditure in healthy, active individuals.

Ten subjects underwent two testing sessions (i.e. cross-over trial) and were given either 3 capsules of MELTDOWN® or 3 capsules of a PLACEBO. The analysis revealed a significant difference in energy expenditure between those subjects given MELTDOWN (1.28 kcal∙min-1) vs. The PLACEBO (a mere 1.00 kcal∙min-1) during the three-hour study. There was also an increase in fat utilization in the MELTDOWN group.

According to the investigators, “results indicate a significant increase in energy expenditure in young, healthy individuals following an acute ingestion of a weight loss supplement.”

VPX TO FUND MORE RESEARCH

This clinical trial is just the first of several clinical trials that will be funded by VPX and completed within 2009. Other flagship products such as REDLINE® and NO-Shotgun® are currently being studied. Once you have the results, fire them over here!

VPX owner Jack Owoc was quoted as saying: “We’re thrilled about the results of this clinical trial. The crossover design of this study shows indeed that the MELTDOWN® treatment had a profound effect; furthermore, we have several additional clinical trials in progress. Our commitment to science is second to none.”

The results of this investigation were presented at The International Society of Sports Nutrition (ISSN) Conference (http://www.sportsnutritionsociety.org) which is the leading academic, non-profit society dedicated to the science and application of sports nutrition.